Magazine Article | November 1, 2023

AI & ML: A Review Of EMA And FDA's Approach

Source: Life Science Leader

By Sean Hilscher and Tanvi Mehta

Considering the feverish pace of innovation in the field of AI and the inevitable impact this family of technologies has on medical product development (specifically drug development), an overview of the approaches to AI/ML regulation by leading medical product regulatory authorities, the FDA and EMA, is timely. Below we outline the documents and guidances the two regulators have released thus far, comparing and contrasting their areas of focus and concern.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader